Oxford BioMedica PLC (OXBDF)

[marcusl2]

09:35 Design of a Highly Efficacious CAR Targeting Mesothelin in Solid Tumors

Boris Engels, PhD, Senior Investigator, Exploratory Immuno-Oncology, Novartis, Inc.

Following clinical experience with a murine scFv based CAR (SS1) targeting mesothelin (MSLN), we pursued the generation of a fully human MSLN-targeting CAR with increased potency against solid tumors. The strong anti-tumor activity of the lead CAR was confirmed in a unique primary pancreatic cancer xenograft mouse “clinical trial”. The lead candidate is now being evaluated in a Phase I clinical study in patients with malignant mesothelioma, ovarian, and lung cancer.